Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.

NCT06855589 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer (Adenocarcinoma)

Interventions

DRUG: 6 months of Eligard
DRUG: 12 months of Eligard
RADIATION: prostate SBRT or prostate brachytherapy with radiation therapy

Sponsor

Charles LeMoyne Hospital